secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sight Sciences, Inc. (SGHT)
CIK:        0001531177
Form:       8-K
Filed at:   2026-08-05T20:09:46+00:00
Accession:  0001193125-26-335092
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sight Sciences Q2 revenue $23.4M (+20% YoY); raises FY2026 revenue guidance to $88-92M
--------------------------------------------------------------------------------

- Q2 revenue $23.4M (+20% YoY); IG $20.7M (+8%), IDE record $2.7M (+704%).
- Net loss improved to $4.4M ($0.08 loss per share) from $11.9M ($0.23) YoY.
- Raised FY2026 revenue guidance to $88-92M (prior $83-89M); reduced adjusted opex guidance to $92-94M.
- Cash usage $5.2M in Q2, down 28% YoY; cash $79.8M; debt $40M.
- FDA 510(k) clearance for OMNI Ultra; Aetna coverage for implant-free glaucoma procedures.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1531177/000119312526335092/0001193125-26-335092-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1531177/000119312526335092/sght-20260805.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-335092

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer